Thr role of T-cell costimulatory activation pathways in transplant rejection

New England Journal of Medicine

Volumn 338, Issue 25, 1998, Pages 1813-1821

  Sayegh, Mohamed H ^a   Turka, Laurence A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 39; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; TACROLIMUS; B7 ANTIGEN; CD40 ANTIGEN;

CLINICAL TRIAL; DRUG MECHANISM; EXPERIMENTAL TRANSPLANTATION; GRAFT REJECTION; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC DISORDER; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD40; ANTIGENS, CD80; GRAFT REJECTION; HUMANS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0032543306     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199806183382506     Document Type: Review

References (55)

1. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993;270:1339-43.
2. Cecka JM. The UNOS scientific renal transplant registry. In: Cecka JM, Terasaki PI, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1996:1-14.
3. Paul LC, Tilney NL. Alloantigen-dependent events in chronic rejection. In: Tilney NL, Strom TB, Paul LC, eds. Transplantation biology: cellular and molecular aspects. Philadelphia: Lippincott-Raven, 1996:567-75.
4. Tilnev NL, Paul LC. Antigen-independent events leading to chronic graft dysfunction. In: Tilney NL, Strom TB, Paul LC, eds. Transplantation biology: cellular and molecular aspects. Philadelphia: Lippincott-Raven, 1996:629-37.
5. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990;322: 510-7.
6. Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76:275-85.
7. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335:1369-77.
8. Savegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994;57: 1295-302.
9. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990;11:83-8.
10. Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998;101:398-405.
11. Vella JP, Spadafora-Ferreira M, Murphy B, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64:795-800.
12. Krieger NR, Yin DP, Garrison Fathman C. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 1996;184:2013-8.
13. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994;331:365-76.
14. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today 1992;13:136-42.
15. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70 kd S6 protein kinases. Cell 1992;69:1227-36.
16. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996;8:710-20.
17. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995;17:615-20.
18. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993;259:974-7.
19. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
20. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-31.
21. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
22. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-50.
23. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A 1993;90:6586-90.
24. Noel PJ, Boise LH, Green JM, Thompson CB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996;157: 636-42.
25. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-73.
26. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80 and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A 1996;93:13967-72.
27. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15:406-11.
28. Reul RM, Fang JC, Denton MD, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 1997;64:1765-74.
29. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177:925-35.
30. Guo Y, Wu Y, Shinde S, Sy MS, Aruffo A, Liu Y. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med 1996;184:955-61.
31. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257: 789-92.
32. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992;89:11102-5.
33. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-6.
34. Savegh MH, Zheng X-G, Magee C, Hancock WW, Turka LA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treafed murine cardiac allograft recipients. Transplantation 1997;64:1646-50.
35. Pearson TC, Alexander DZ, Hendrix R, et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model: evidence for hematopoietic chimerism. Transplantation 1996;61:997-1004.
36. Savegh MH, Alcalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995;181:1869-74.
37. Perez V, Parijs LV, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6:411-7.
38. Perico N, Amuchastegui S, Bontempelli M, Remuzzi G. CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. Transplantation 1996;61:1320-2.
39. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-55.
40. Zheng XX, Sayegh MH, Zheng X-G, et al. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol 1997;159:1169-73.
41. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995;155:1165-74.
42. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac reaction in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996;97:833-8.
43. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimulation prevents development of experimental chronic allograft rejection. Proc Natl Acad Sci U S A 1996;93:12439-44.
44. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation 1997;63:1053-8.
45. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997;100:1199-203.
46. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61:4-9.
47. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 1995;92:9560-4.
48. Pearson TC, Routenberg KL, Abrams J, Linsley PS, Larsen CP. Prolongation of renal allograft survival with CTLA4Ig in the rhesus macaque. In: Program and abstracts of the 17th American Society of Transplant Physicians Annual Meeting, Chicago, May 11-14, 1997:85. abstract.
49. Levisetti M, Padrid P, Szot G, et al. Immunosuppressive effects of hCTLA4Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation. J Immunol 1997;159:5187-91.
50. Chang AC, Blum MG, Scott M, Thomas DW, Pierson RN. Antibody to CD40 ligand prolongs primate cardiac allograft survival. In: Program and abstracts of the 23rd American Society of Transplant Surgeons Annual Meeting, Chicago, May 14-16, 1997:A-41. abstract.
51. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94:8789-94.
52. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:343-8.
53. Lebwohl M, Kang S, Guzzo C, et al. CTLA4Ig (BMS-188667)-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J Invest Dermatol 1997;108:570. abstract.
54. Woodward JE, Qin L, Chavin KD, et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation 1996;62:1011-8.
55. Yin D, Fathman CG. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. J Immunol 1995; 155:1655-9.